NeuroSense receives approval in Germany to enroll patients in Paradigm study

NeuroSense Therapeutics announced that Germany’s Federal Institute for Drugs and Medical Devices, or BfArM, approved the Company’s Clinical Trial Application, or CTA, to enroll patients in PARADIGM, its Phase 2b study of its lead combination drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis, or ALS. PARADIGM is a Phase 2b randomized, multi-center, multinational, prospective, double-blind, placebo-controlled study, with an open-label extension, to evaluate the safety, tolerability, and efficacy of PrimeC. To date, over 50% of the planned 69 study participants have been enrolled.